| Literature DB >> 25273598 |
Ian P Olwoch, Oppel B W Greeff, Gisela Jooné, Vanessa Steenkamp.
Abstract
BACKGROUND: Pectinex Ultra SP-L (Pectinex) is a microbial-derived enzyme that is used in the food industry and that has been shown to inhibit bacterial biofilms. It has been suggested that Pectinex may be useful in the management of biofilm-related bacterial infections and therefore warrants further investigation in this regard. The aim of this study was to investigate the cytotoxicity of Pectinex on cervical adenocarcinoma cells (HeLa), lymphocytes and neutrophils. Cell viability and morphology were assessed using an in vitro spectrophotometric MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) assay and polarization-optical transmitted light differential interference contrast microscopy. This study also investigated the antibacterial and antibiofilm actions of Pectinex, alone and in combination with antibiotics, on standard and clinical cultures of Staphylococcus aureus and Pseudomonas aeruginosa. Minimum inhibitory (MIC) and bactericidal (MBC) concentrations were determined using p-iodo-nitrotetrazolium violet staining of bacterial cultures and regrowth of subcultures. Biofilm biomass and cell viability were quantified spectrophotometrically after staining with crystal violet and MTT.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25273598 PMCID: PMC4189667 DOI: 10.1186/s12866-014-0251-1
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
MIC and MBC of antibiotics alone, and in antibiotic-Pectinex combinations (checkerboard), against and
|
|
| |||
|---|---|---|---|---|
|
|
|
|
| |
| MIC | 0.42 (±0.08) | 2.0 (±0.0) | 0.13 (±0.0) | 1.0 (±0.0) |
| MBC | 0.50 (±0.0) | 2.0 (±0.0) | 0.33 (±0.08) | 1.67 (±0.33) |
| Checkerboard MIC | 0.42 (±0.04) | 2.56 (±0.38) | 0.12 (±0.01) | 1.89 (±0.11) |
| Checkerboard MBC | 0.56 (±0.09) | 2.56 (±0.38) | 0.32 (±0.05) | 3.22 (±0.40) |
[Results expressed as mean ± SEM].
Figure 1Percentage inhibition ± SEM after Pectinex challenge in HeLa cells [A], non-stimulated (NS) and fMLP-stimulated lymphocytes [B] and neutrophils [C].
Figure 2PlasDIC microscopy images (x400 magnification) after 24 h treatment with Pectinex 237.5 PGU/ml and in untreated controls. A: HeLa cell control; B: HeLa cells treated; C: Lymphocyte control; D: Lymphocytes treated; E: Neutrophil control; F: Neutrophils treated.
Figure 3Mean percentage (%) inhibition ± S.E.M. of biofilm formation by ATCC strain after 6 h incubation with [A] Pectinex, [B] ciprofloxacin, [C] Pectinex 950 PGU/ml plus ciprofloxacin, and [D] Pectinex 7.42 PGU/ml plus ciprofloxacin (*indicates where p ≤ 0.05 compared to untreated controls).
Figure 4Scanning electron microscopy (x5000 magnification) of ATCC after incubation from 0 – 24 h (A – D) and 24 – 48 h (E – H).